Intermittent hypoxia-activated cyclooxygenase pathway: Role in atherosclerosis

European Respiratory Journal

Volumn 42, Issue 2, 2013, Pages 404-413

  Gautier Veyret, Elodie ^a,b   Arnaud, Claire ^a   Báck, Magnus ^c   Pépin, Jean Louis ^a,b,d   Petri, Marcelo H ^c   Baguet, Jean Philippe ^b,d   Tamisier, Renaud ^a,b,d   Lévy, Patrick ^a,b,d   Stanke Labesque, Franćoise ^a,b,d  

^a INSERM   (France)

^b HÔPITAL MICHALLON   (France)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIV GRENOBLE ALPES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; APOLIPOPROTEIN E; CYCLOOXYGENASE 1; MESSENGER RNA; PROSTAGLANDIN SYNTHASE; THROMBOXANE SYNTHASE;

ADULT; AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; BODY MASS; CARDIOVASCULAR RISK; CONCENTRATION (PARAMETERS); FEMALE; GENE EXPRESSION; HUMAN; INTERMITTENT HYPOXIA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SLEEP DISORDERED BREATHING;

ADULT; ANIMALS; ANOXIA; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BODY MASS INDEX; BODY WEIGHT; CASE-CONTROL STUDIES; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEMATOCRIT; HUMANS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; PYRAZOLES; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE; THROMBOXANE B2;

EID: 84882638568     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00096512     Document Type: Article

References (30)

1. Dematteis M, Godin-Ribuot D, Arnaud C, et al. Cardiovascular consequences of sleep-disordered breathing: contribution of animal models to understanding the human disease. ILAR J 2009; 50: 262-281.
2. Baguet JP, Hammer L, Lévy P, et al. The severity of oxygen desaturation is predictive of carotid wall thickening and plaque occurrence. Chest 2005; 128: 3407-3412.
3. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/ American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol 2008; 52: 686-717.
4. Jun J, Reinke C, Bedja D, et al. Effect of intermittent hypoxia on atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2010; 209: 381-386.
5. Arnaud C, Poulain L, Lévy P, et al. Inflammation contributes to the atherogenic role of intermittent hypoxia in apolipoprotein-E knock out mice. Atherosclerosis 2011; 219: 425-431.
6. Savransky V, Nanayakkara A, Li J, et al. Chronic intermittent hypoxia induces atherosclerosis. Am J Respir Crit Care Med 2007; 175: 1290-1297.
7. Lefebvre B, Pépin JL, Baguet JP, et al. Leukotriene B4: early mediator of atherosclerosis in obstructive sleep apnoea? Eur Respir J 2008; 32: 113-120.
8. Stanke-Labesque F, Pepin JL, de Jouvencel T, et al. Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea. J Lipid Res 2012; 53: 1944-1951.
9. Stanke-Labesque F, Ba?ck M, Lefebvre B, et al. Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia. J Allergy Clin Immunol 2009; 124: 364-370.
10. Capra V, Ba?ck M, Barbieri SS, et al. Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke. Med Res Rev 2013; 33: 364-438.
11. Cyrus T, Sung S, Zhao L, et al. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2002; 106: 1282-1287.
12. Belton OA, Duffy A, Toomey S, et al. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 2003; 108: 3017-3023.
13. McClelland S, Gawaz M, Kennerknecht E, et al. Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse. Atherosclerosis 2009; 202: 84-91.
14. Kobayashi T, Tahara Y, Matsumoto M, et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004; 114: 784-794.
15. Montine TJ, Sonnen JA, Milne G, et al. Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT. PLoS One 2010; 5: e9340.
16. Ba?ck M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur Heart J 2012; 33: 1928-1933.
17. Krieger J, Benzoni D, Sforza E, et al. Urinary excretion of prostanoids during sleep in obstructive sleep apnoea patients. Clin Exp Pharmacol Physiol 1991; 18: 551-555.
18. Kimura H, Niijima M, Abe Y, et al. Compensatory excretion of prostacyclin and thromboxane metabolites in obstructive sleep apnea syndrome. Intern Med 1998; 37: 127-133.
19. Ba?ck M, Sultan A, Ovchinnikova O, et al. 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res 2007; 100: 946-949.
20. Holt RI. International Diabetes Federation re-defines the metabolic syndrome. Diabetes Obes Metab 2005; 7: 618-620.
21. Hosselet J, Ayappa I, Norman RG, et al. Classification of sleep-disordered breathing. Am J Respir Crit Care Med 2001; 163: 398-405.
22. Casetta B, Vecchione G, Tomaiuolo M, et al. Setting up a 2D-LC/MS/MS method for the rapid quantitation of the prostanoid metabolites 6-oxo-PGF(1a) and TXB2 as markers for hemostasis assessment. J Mass Spectrom 2009; 44: 346-352.
23. Li J, Thorne LN, Punjabi NM, et al. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res 2005; 97: 698-706.
24. Caughey GE, Pouliot M, Cleland LG, et al. Regulation of tumor necrosis factor-a and IL-1b synthesis by thromboxane A2 in nonadherent human monocytes. J Immunol 1997; 158: 351-358.
25. Cyrus T, Ding T, Praticò D. Expression of thromboxane synthase, prostacyclin synthase and thromboxane receptor in atherosclerotic lesions: correlation with plaque composition. Atherosclerosis 2010; 208: 376-381.
26. Arnaud C, Beguin PC, Lantuejoul S, et al. The inflammatory preatherosclerotic remodeling induced by intermittent hypoxia is attenuated by RANTES/CCL5 inhibition. Am J Respir Crit Care Med 2011; 184: 724-731.
27. Lavie L. Oxidative stress inflammation and endothelial dysfunction in obstructive sleep apnea. Front Biosci (Elite Ed) 2012; 4: 1391-1403.
28. Davì G, Guagnano MT, Ciabattoni G, et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288: 2008-2014.
29. Minuz P, Patrignani P, Gaino S, et al. Determinants of platelet activation in human essential hypertension. Hypertension 2004; 43: 64-70.
30. Choi JH, Jeon HJ, Park JG, et al. Anti-atherogenic effect of BHB-TZD having inhibitory activities on cyclooxygenase and 5-lipoxygenase in hyperlipidemic mice. Atherosclerosis 2010; 212: 146-152.